Overview

* Karyopharm Q3 total revenue rises to $44 mln, driven by XPOVIO sales growth

* Net loss for Q3 2025 was $33.1 mln, slightly higher than last year

* Company reaffirms full-year 2025 revenue guidance of $140 mln to $155 mln

Outlook

* Karyopharm reaffirms 2025 total revenue guidance of $140 mln to $155 mln

* Company expects 2025 U.S. XPOVIO revenue of $110 mln to $120 mln

* Karyopharm lowers 2025 R&D and SG&A expenses to $235 mln to $245 mln

Result Drivers

* XPOVIO SALES - U.S. net product revenue for XPOVIO increased by 8.5% compared to Q3 2024, driven by consistent demand in the community setting

* GLOBAL ACCESS - Expanded global patient access for selinexor led to growth in royalty revenue from international partners

* LICENSE REVENUE - Increase in license and other revenue was driven by milestone-related revenue from Menarini

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $32.03

Product mln

Revenue

Q3 Net -$33.12

Income mln

Q3 $59.26

Operatin mln

g

Expenses

Q3 -$15.22

Operatin mln

g Income

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)